Directorio

We are doing this study to find out if an experimental drug called CT01681 (the study drug) is a safe and effective option for people who get CAR T-cell therapy as a treatment for diffuse large B cell lymphoma (DLBCL). We want to know if the study drug has the potential to lower or prevent certain side effects of CAR T-cell therapy. The possible side effects of CAR T-cell therapy that the study drug is being developed to protect against are called cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. This study is enrolling people who will receive an available form of CAR T-cell therapy called YESCARTA.

We are doing this study to see if an experimental combination of drugs (D2C7-IT and 2141-V11) is a safe treatment for brain tumors.

To join this study, you must have already had surgery to remove as much of your tumor as possible. Once you are in the study, you will have another surgery to take a tiny piece of tissue and place a thin tube called a catheter in your brain where the tumor is. Through this tube, you will get a medicine called D2C7-IT for three days. Then you will get another medicine called 2141-V11 for about seven hours. About two weeks later, you will start getting shots of 2141-V11 under your skin near the lymph nodes in your head and neck. You will get another shot two weeks after that, and then shots every four weeks for up to a year. After that, you may keep getting shots every 4 to 6 weeks if you want.

To join this study, you will go to Duke hospital for surgery. During surgery, doctors will place a small tube called a catheter to give you the study medicine and take a tiny piece of tissue for research. After surgery, you will stay in the hospital while the first medicine, called D2C7-IT, goes in for about three days. Then you will get another medicine called 2141-V11, which takes about seven hours. After the medicines are done, the tube will be removed, and you will be watched for six hours. About two weeks later, you will come back to start getting shots of 2141-V11 under your skin. You may keep getting these shots for up to a year, and even longer if you want. When you stop the shots, your doctor will decide what follow-up you need.

We are doing this study to learn more about the use of the da Vinci Single-Port Surgical System in nipple-sparing mastectomy (NSM) procedures. We want to find out if the outcomes of NSM using this robotic-assisted technology are better than the current standard of open surgery.

We are doing this study to collect information about how well dabrafenib plus trametinib works in patients who have unresectable (cannot be removed by surgery) or metastatic BRAF V600E mutation positive solid tumors.

We are doing this study to find out if the combination of the drugs Dapansutrile and Pembrolizumab is a safe and effective treatment for people with melanoma that does not improve after PD-1 therapy.

We are doing this study to collect and store information and samples that will be used for future research studies about transplants.